Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma
Abstract
To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) in 81 patients (53 males and 28 females) with high or very high cardiovascular risk (according to the SCORE risk chart) and mixed dyslipidemia, which was defined as having 2 of the following 3 lipid abnormalities in mmol/l: LDL-cholesterol (ch) more than 2.5, HDL-ch less than 1 in males and 1,2 in females, triglycerides (TG) more than 1.7. About 44% of those patients had type 2 diabetes mellitus and 30% had impaired fasting glucose.
Six-month combined therapy was tolerated very well and reduced LDL-ch by 29%, TG by 40% but HDL-ch increase was noty significant (by 3%). Atherogenic index of plasma: AIP = log(TG/HDL-ch), was decreased significantly in the majority of the patients.
It is clear from the study,that more intensive managements of mixed dyslipidemia is needed in those patients.